Dr. Luis Garegnani from Argentia wrote an opinion piece on Ivermectin not having enough evidence behind it in BMJ Journals. Dr. Pierre Kory of the FLCCC disagrees. Both doctors debate this issue with Dr. Erin Stair as the moderator. About Luis Garegnani: Luis Garegnani is a Professor of Research methods and evidence-based medicine at Instituto…
Tag: Drugs
Open Forum Infectious Disease reports “Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection”
Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and…
Mercola reports “More Good News on Ivermectin”
Ivermectin is an antiparasitic drug that may be even more useful against COVID-19 than hydroxychloroquine (HCQ). However, like HCQ, use of ivermectin has been globally suppressed, discouraged and even warned against, despite decades of safe use for other ailments In the U.S., the Frontline COVID-19 Critical Care Alliance (FLCCC) has been calling for widespread adoption…
Front Line COVID-19 Critical Care Alliance reports “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19”
In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered thativermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties…
Front Line COVID-19 Critical Care Alliance reports “Ivermectin is Now a Treatment Option for Health Care Providers!”
Jan 14, 2021 – One week after Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line COVID-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their…
Real Clear Politics reports “The Tragic Hydroxychloroquine Debate and Dr. Fauci’s Denial of Evidence”
As an epidemiologist trained to make causal inference, especially from observations, I feel strongly that there is an urgent need for an open and honest debate on the ability of hydroxychloroquine (HCQ) to save lives. I had not paid much attention to discussions related to the efficacy of pharmacological interventions in the treatment of Covid-19…
Rolling Stone reports “Big Pharma’s Covid-19 Profiteers”
How the race to develop treatments and a vaccine will create a historic windfall for the industry — and everyone else will pay the price On June 29th, 2020, while America remained transfixed by anti-police protests, the chairman and CEO of the pharmaceutical company Gilead issued a much-anticipated announcement. In a breezy open letter, Daniel O’Day…
Lanier Law Firm reports “TAMIFLU FRAUD BILKED $1.5 BILLION FROM GOVERNMENT, ALLEGES WHISTLEBLOWER”
Drug company Hoffmann-La Roche (OTCMKTS – RHHBY) bilked U.S. federal and state governments out of $1.5 billion by misrepresenting clinical studies and falsely claiming that its well-known influenza medicine Tamiflu was effective at containing potential pandemics, according to a recently unsealed whistleblower lawsuit. The lawsuit claims the drugmaker’s scheme involved publishing misleading articles falsely stating that Tamiflu reduces complications, severity, hospitalizations,…
Stat News reports “The U.S. government contributed research to a Gilead Remdesivir patent — but didn’t get credit”
Two documents dating back to 2015 shed further light on the role the federal government played in discovering remdesivir and its use in treating coronaviruses — work that has taken on new meaning as the Gilead Sciences (GILD) drug has gained global attention and an emergency use authorization from federal regulators to treat patients with…
Harvard University reports “Risky Drugs: Why The FDA Cannot Be Trusted”
A forthcoming article for the special issue of the Journal of Law, Medicine and Ethics (JLME), edited by Marc Rodwin and supported by the Edmond J. Safra Center for Ethics, presents evidence that about 90 percent of all new drugs approved by the FDA over the past 30 years are little or no more effective for patients than existing drugs. All…